High Content Screening

High content screening
#AI / data analytics / healthtech / informatics #High Content Screening #Imaging

Accelerating drug discovery: The impact of ultra-fast screening

This paid-for advertorial by Araceli Biosciences appeared in DDW Volume 25 – Issue 4, Fall 2024 Read the digital issue Accelerating discovery with real-time laboratory data  In the era of artificial intelligence (AI), biotech R&D is hungry for data like never before. Machine learning (ML) is transforming innovation: faster discovery,… Read More

#Exclusive Content

#3D cell culture #Drug discovery #Ex Vivo #Genomics #High Content Screening #Life sciences #Molecular Biology #Precision medicine

Podcast: Finding the right cancer drug with high-content screening

This is the latest episode of the free DDW podcast, “Finding the right cancer drug with high-content screening”. It covers an article by the same name written for Volume 23, Issue 1 – Winter 2021/22 of DDW. In the article, Lassi Paavolainen, Principal Investigator at the Institute for Molecular… Read More

#News

#Cell painting #Drug discovery #High Content Screening

Cell painting: a vibrant future for phenotypic drug discovery

The cell painting approach evokes new ideas and strategies for high-content screening (HCS) practitioners to identify new drugs and to study mechanisms of action by leveraging machine learning to measure subtle phenotypic changes at the cellular level. Dr. Alexander Schreiner, HCS Applications Leader, PerkinElmer and Dr. Martin Daffertshofer, High Content… Read More

#Exclusive Content

#Cell painting #Cellular imaging #High Content Screening #Reagents

PerkinElmer launches first cell painting kit

PerkinElmer has launched the first cell painting kit as part of its new portfolio of PhenoVue cellular imaging reagents. This new range of reagents leverages PerkinElmer’s expertise in cellular imaging and high-content screening and works alongside its microplates, automation, software and high-content screening instruments. With this entire screening workflow, researchers… Read More

#News

#Assay development optimisation & technology #Drug discovery #High Content Screening #RNA

PerkinElmer to acquire Horizon Discovery for $383 million

PerkinElmer will acquire Horizon Discovery for approximately $383 million (£296 million). The transaction is expected to close in the first quarter of 2021 subject to conditions. The investment will allow PerkinElmer to expand its portfolio of leading, automated life sciences discovery and applied genomics solutions to include gene editing and… Read More

#News #Trending News

#Academic #AI / data analytics / healthtech / informatics #Animal models #Biomarkers #Business #Cell therapy #Cellular & Molecular biology #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Combinatorial chemistry #Drug development #Drug discovery #Drug repositioning #Gene therapy #Genetics / genomes #High Content Screening #High throughput screening #Immunology #Immunology / Virology & Vaccines #Lead discovery #Molecular medicine #PCR #RNA #Screening #Stem cells #System biology #Systems biology #Therapeutics #Translational #Translational chemistry

Race To COVID-19 cure – the Core Model for solving the pandemic crisis (Part 1 & 2)

By Ibis Sanchez-Serrano and Rathnam Chaguturu Mitigation of COVID-19 pandemic requires a combination of effective epidemiological policies and the discovery/development of powerful drugs against the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) that causes this disease. This article examines the major initiatives being explored at the… Read More

#Covid-19 #Exclusive Content

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Chemistry #Clinical specialities #Clinical trials #Genetics / genomes #High Content Screening #Immunology / Virology & Vaccines #Pathology #Preclinical #Stem cells #Target validation #Therapeutics

The COVID-19 race: how mouse models will help researchers cross the finish line

THE COVID-19 RACE how mouse models will help researchers cross the finish line By Dr Megan MacBride The emergence of SARS-CoV-2 virus and the disease it causes, COVID-19, have fuelled significant shifts in preclinical research across the globe. Amid the worldwide health emergency created by high… Read More

#Covid-19 #Exclusive Content

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biomarkers #Cellular & Molecular biology #Cellular assays #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomes #High Content Screening #High throughput screening #Imaging #Immunology #Immunology / Virology & Vaccines #Lead discovery #Microbiology #Molecular medicine #Protein chemistry / Proteomics #RNA #Screening #Stem cells #System biology #Systems biology #Therapeutics #Toxicology

High content screening in action: a powerful tool to identify novel antivirals and vaccines

By Dr Karin Bottcher High content screening (HCS) has played a significant role in infectious disease research and drug discovery to date and can be a strong tool in the age of COVID-19 and beyond. With a focus on viral diseases, this article… Read More

#Covid-19 #Exclusive Content

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Business #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #Gene therapy #Genomics #High Content Screening #High throughput screening #Immunology / Virology & Vaccines #Lead discovery #Lead optimisation #Mass spectrometry / NMR #Medicinal chemistry #Molecular medicine #Organic chemistry #Pharmokinetics #Precision medicine #RNA #Screening #System biology #Systems biology #Therapeutics #Toxicology

The COVID-19 antiviral race: we’re all in this together

The COVID-19 antiviral race: we’re all in this together By Uduak Grace Thomas In response to the COVID-19 pandemic, international scientists from academia and industry have pooled their expertise and resources to identify candidate compounds that inhibit the activity of the SARS-CoV-2 main protease, in order to develop… Read More

#Covid-19 #Exclusive Content

#Academic #AI / data analytics / healthtech / informatics #Animal models #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Cell / tissue culture #Cell culture #Cellular assays #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #High Content Screening #High throughput screening #Imaging #Lead discovery #Pharmokinetics #Preclinical #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry

The CELL CULTURE innovations increasing drug discovery success

The CELL CULTURE innovations increasing drug discovery success By Helen Stewart-Miller and Abby George Volume 21 Issue 3 – Summer 2020 ‘Fail early, fail fast’ has been a mantra in the pharmaceutical industry for several years and directly impacts the overall strategy of many drug discovery and development… Read More

#Exclusive Content

#Academic #Analysis #Biomarkers #Clinical trials #Drug development #Gene therapy #Genomics #High Content Screening #Therapeutics

The Personalized Medicine Coalition

The Personalized Medicine Coalition The Personalized Medicine Coalition (PMC), representing a broad spectrum of academic, industrial, patient, provider, and payer communities, seeks to advance the understanding and adoption of personalized medicine concepts and products for the benefit of patients. As part of its… Read More

#Archive

#Academic #Analysis #Assay development optimisation & technology #Cell culture #Cellular assays #Chemistry #Drug discovery #Drug targets #Genetics / genomes #High Content Screening #High throughput screening #Immunology #Lead discovery #Medicinal chemistry #PCR #Pharmacology #RNA #Screening #Stem cells #System biology

Guidelines & Recommendations For Analyzing and Interpreting GPCR Second Messenger Data

Guidelines & Recommendations For Analyzing and Interpreting GPCR Second Messenger Data Sponsored by CisBio The question of choosing which methods to use for analyte quantification (signal vs concentration determination, parameters, and format) continues to generate heated debates and divergent understanding. Today, there is still… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Automation / robotics #Business #Chemical engineering #Chemistry #Drug discovery #High Content Screening #High throughput screening #Lead discovery #RNA #Screening

Unleashing High-Throughput Reaction Screening The Unchained way

Unleashing High-Throughput Reaction Screening The Unchained way Sponsored by Unchained Labs A successful high-throughput approach to reaction screening requires rational and systematic exploration of a broad set of variables to achieve optimization expeditiously. There are many types of potential variables that can be screened. Even with… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development & optimisation #Assay development optimisation & technology #Biochemistry #Bioengineering #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Combinatorial chemistry #Drug development #Drug discovery #Gene therapy #Genetics / genomes #Genetics / genomics #High Content Screening #High throughput screening #Imaging #Lead discovery #Protein chemistry / Proteomics #Regenerative Medicine #Regulatory #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology

Stem Cell Differentiation

Stem Cell Differentiation By Dr Lilian Hook Stem cells are extraordinary cells, capable of both self-renewal and differentiation to mature somatic cells in vivo and in vitro (1,2). They have many features and advantages which could revolutionise drug development and healthcare applications. Read More

#Archive

#Analysis #Automation / robotics #Biomarkers #Business #Cell / tissue culture #Cell culture #Cellular & Molecular biology #Cellular assays #Clinical specialities #Drug discovery #Drug targets #Genetics / genomes #Genomics #High Content Screening #High throughput screening #Imaging #Lead discovery #Molecular medicine #Protein chemistry / Proteomics #RNA #Screening #Stem cells #System biology #Systems biology #Toxicology

Phenotypic Drug Discovery With High Content Screening

Phenotypic Drug Discovery With High Content Screening Sponsored by PerkinElmer Early drug discovery used to be conducted mainly in a target-agnostic fashion, focusing on qualitative readouts from a living system – cells, tissue, or organisms – and asking the question, did this entity affect the phenotype?… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Business #Cell therapy #Cellular & Molecular biology #Cellular assays #Clinical specialities #Drug development #Drug discovery #Drug targets #Gene therapy #High Content Screening #Molecular medicine #Oncology #Protein chemistry / Proteomics #RNA #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology

Targeting Energy Metabolism for Cancer Therapeutic Discovery using Agilent Seahorse XF Technology

Targeting Energy Metabolism for Cancer Therapeutic Discovery using Agilent Seahorse XF Technology Sponsored by Agilent This white paper discusses targeting energy metabolism for cancer therapeutic discovery using Agilent Seahorse XF technology. Abstract Altered energy metabolism is now recognized as a driver… Read More

#Archive